---
title: "Vancomycin HCI: Class II recall update"
id: "fda-98636"
canonical_url: "https://medichelpline.com/clinical-feed/fda-98636"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "FDA MedWatch"
source_url: "https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=98636"
published_at: "2026-04-15T12:00:00.000Z"
evidence_level: "Class II"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Vancomycin HCI: Class II recall update
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/fda-98636
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** FDA MedWatch
- **Source URL:** [Original Journal Publication](https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=98636)
- **Published At:** 2026-04-15T12:00:00.000Z
- **Evidence Rating:** Class II
## Executive GIST (TL;DR)
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
## Clinical Analysis & Structured Key Points
Product: Vancomycin HCI Classification: Class II Reason for recall: Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port Product description: Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5085-01 Recalling firm: Fagron Compounding Services Product type: Drugs
## Related Clinical Research

- [Ion‑Programmed J‑Aggregates Enable On‑Demand Phototherapy for Diabetic MRSA Wounds](https://medichelpline.com/clinical-feed/pubmed-42695131.md) (DOI: 10.1002/anie.1142645)
- [Surface charge effects of BSA-curcumin nanoparticles with amikacin in photodynamic therapy for MDR](https://medichelpline.com/clinical-feed/pubmed-42837086.md) (DOI: 10.1007/s10103-026-05054-5)
- [Admission interleukin-6 and short-term prognosis in hospitalized cirrhosis: etiology-dependent, ti](https://medichelpline.com/clinical-feed/plos-one-19-admission-interleukin-6-as-a-time-limited-etiology-dependent-prognostic-signal.md)
- [Ticagrelor Pharmacokinetics Unaffected by Gut Microbiota: Human, In Vitro, and PGF Rat Evidence](https://medichelpline.com/clinical-feed/plos-one-10-ticagrelor-and-gut-microbiota-absence-of-pharmacokinetic-interaction-in-vitro.md)
- [Fatal Rickettsia parkeri Infection in an Immunocompromised Child — Georgia Case Report](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-1-fatal-rickettsia-parkeri-rickettsiosis-in-immunocompromised-pediatric-patient.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.